Investigating the mechanisms of polymyxin-induced toxicity: a multi-omics study

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100051168

Enrollment

Unknown

Registered

2021-09-15

Start date

2021-09-14

Completion date

Unknown

Last updated

2022-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gram-negative bacterial infections

Interventions

nephrotoxicity or lung toxicity group vs. non nephrotoxicity or lung toxicity:Nil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. 2-3 days after receiving intravenous infusion of polymyxin, nephrotoxicity was diagnosed according to the 2012 KDIGO criteria; 2. After receiving aerosol inhalation polymyxin treatment, there were respiratory adverse events such as bronchospasm and cough.

Exclusion criteria

Exclusion criteria: 1. Received other drugs that can induce nephrotoxicity/pulmonary toxicity; 2. Allergy to polymyxin; 3. Malignant tumor; 4. Pregnant subjects and lactating subjects; 5. Can not cooperate with the subject research.

Design outcomes

Primary

Measure	Time frame
Nephrotoxicity;Lung toxicity;	—

Countries

China

Contacts

Public ContactLiu Xueyan

Shenzhen People's Hospital

liuxueyandr@163.com+86 18025388894

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026